Want to join the conversation?
$PFE said the U.S. FDA granted a priority review status for a supplemental new drug application for XALKORI (crizotinib) for treatment of ROS1-positive tumors in patients with non-small cell lung cancer. XALKORI received breakthrough therapy designation by the FDA for this indication in Apr. 2015. The likely FDA action date is April 2016.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)